The University of Maryland Medical Center has officially opened a new cancer center in downtown Baltimore that will not only treat more people, but offer broader access to the latest experimental therapies, some which may be patients’ only hope.

The cancer center, which was dedicated Tuesday, will take up six floors of a new $500 million glass-and-metal building constructed in front of the hospital that has been years in the making.

Cancer remains the nation’s second-largest killer, meaning there’s no shortage of need to treat the disease — and need to find new ways to combat it.

The center, operated by the hospital and the affiliated university’s school of medicine, consolidates services that had been spread around the hospital campus and doubles the space.

Advertise with us

Researchers have already been adding trials and patients from Maryland and the surrounding region, many with complex and advanced cancers, said Dr. Ranee Mehra, the center’s associate director for clinical research and director of head and neck oncology.

“Having this new space in the cancer center will help us tremendously as we grow,” said Mehra, adding that about 20% more patients are expected to be enrolled in trials this year.

Many new trials involve a type of treatment called immunotherapy, which tailors treatments to patients’ specific genetics. An example is CAR T-cell therapy, where a patient’s own white blood cells are genetically reengineered to destroy cancer cells.

The cancer center, named the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, as well as the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore are both National Cancer Institute-designated comprehensive cancer centers, a status that requires rigorous research standards to receive federal funding.

But Mehra said she anticipates more funding will come through partnership with private industry as federal dollars become more limited.

Advertise with us

The cancer center now has $186.2 million in annual research funding and offers 400 clinical trials.

About 100 faculty members already work in the center, including 10 newcomers. Dr. Nirali Shah recently moved from the National Institutes of Health to the center as associate director for translational research.

Her focus has been on acute myeloid leukemia, a fast-growing cancer of the blood and bone marrow. Immunotherapies have worked well for such blood cancers, but she said they can have side effects and the therapies also work less well on solid tumors.

The University of Maryland Medical Center’s cancer center will move into the new Roslyn and Leonard Stoler Center for Advanced Medicine and offer expanded access to experimental cancer therapies.
The cancer center will take up six floors of a new $500 million glass-and-metal building constructed in front of the hospital. (University of Maryland Medical System)

These will be areas of research, as well as research on treatments specifically for children, said Shah, who is also director of the pediatric/adolescent and young adult cell and gene therapy program at the university’s children’s hospital. The new facilities will mean young patients will not have to travel so far for an experimental therapy.

‘We can utilize the cancer center for everything we want to do to improve access for cancer patients in the younger population,” she said. “They are absolutely underserved.”

Advertise with us

Center researchers also are working to advance treatment for common cancers.

Natacia Wright, a 33-year-old Army veteran and single mother, was able to enter two trials aimed at better treating her breast cancer, discovered last year. There have been positive results so far, though she will need to return to the center for more treatment next year.

“But the biggest thing to me, and I hope it resonates with others, is that I could do my part in progressing medicine and science and reducing the pain and suffering for future women and people,” said Wright, who travels about a half-hour from her Howard County home to receive treatment. “That’s a really big reward.”

The new 14-story Stoler building housing the cancer center broke ground in 2022 after years of planning.

The building is named for Baltimore philanthropists Roslyn and Leonard Stoler, founder of Len Stoler Automotive Group, who provided $25 million of the $288 million cost of the cancer center. The building will eventually include an urgent-care center for cancer patients and other non-cancer services.

Advertise with us

At a dedication Tuesday, Dr. Taofeek K. Owonikoko, the cancer center’s executive director, said the new facility will eventually increase inpatient and outpatient capacity by 40%.

“We know that our patients and their families are facing some of the most challenging moments of their lives,” he said, “and we have created a welcoming environment where they can receive multidisciplinary care from a team of experts and all the support that they need in one location.”